Year-end Sale % OFF 
Abstract
We investigated the role of platelet aggregation on 2-bromoethylamine hydrobromide-induced renal papillary necrosis by using the rats treated with antiplatelet drug. Ten male Sprague-Dawley rats were orally administered with ticlopidine hydrochloride at 300 mg/kg/day for 5 successive days. Ten control rats were orally administered with the vehicle. Five rats in each group were injected intraperitoneally with 2-bromoethylamine hydrobromide at 100 mg/kg at 1 hr after the 3rd administration of ticlopidine or the vehicle and the remaining five rats in each group received saline in the same manner. On the last day of the treatment, blood was collected and ADP-induced platelet aggregation was measured. The kidneys were examined microscopically and the area of total renal papillary necrosis was measured. Platelet aggregation was significantly inhibited in ticlopidine-treated rats. However, renal papillary necrosis was observed in all rats injected with 2-bromoethylamine hydrobromide and there was no difference in the area of renal papillary necrosis between ticlopidine and vehicle-treated groups. These data showed that platelet aggregation did not contribute to the development of 2-bromoethylamine hydrobromide-induced renal papillary necrosis in rats.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
